SCHEMBL7462682

SCHEMBL7462682

Cc1ccc(SC(=O)N(C)c2cccc(Cl)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR3E A5X5Y0 1/20 0.48
▸ HTR3B O95264 1/20 0.48
▸ HTR3A P46098 1/20 0.48
▸ HTR3D Q70Z44 1/20 0.48
▸ HTR3C Q8WXA8 1/20 0.48
▸ HSD17B1 P14061 4/20 0.45
▸ HSD17B2 P37059 4/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ GPBAR1 Q8TDU6 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ LIPE Q05469 1/20 0.37
▸ SCN2A Q99250 1/20 0.37
▸ HCRTR2 O43614 1/20 0.37
▸ CRHR1 P34998 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7459759 0.81 GPBAR1 (0.39) SMN1; SMN2KMT2AGPBAR1MAPTMEN1
SCHEMBL7458789 0.80 MAPT (0.45) HSD17B1HSD17B2SMN1; SMN2MAPTTP53
SCHEMBL8665828 0.73 LMNA (0.53) HSD17B1HSD17B2SMN1; SMN2KMT2AMAPT
SCHEMBL2096196 0.73 HTR3E (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL10802471 0.73 HTR3E (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL2096198 0.73 HTR3E (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6386464 0.73 HTR3E (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL31715773 0.73 HTR3E (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6629827 0.73 HTR3E (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6420779 0.73 ACHE (0.42) HSD17B1HSD17B2SMN1; SMN2KMT2AGPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020188122-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2002-12-12 — — US claimed
EP-1227092-A2 Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties SmithKline Beecham Corporation (US) 2002-07-31 — — EP claimed
EP-1227091-A2 Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties SMITHKLINE BEECHAM CORPORATION (US) 2002-07-31 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188122-A1 Novel compounds IL2, IFNG, IL1RN HTR3E 2586/4885HTR3B 2352/4885HTR3A 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback